This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +)

This study has been completed.
Sponsor:
Collaborator:
Gambro Lundia AB
Information provided by (Responsible Party):
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT01783626
First received: January 28, 2013
Last updated: May 5, 2017
Last verified: April 2013
  Purpose

Evodial +hemodialyzer consists of an evolution of the existing CE marked Evodial device, with respect to the hemodialyzer membrane removal characteristics. Different membrane prototypes configurations are proposed (3 versions in total), with the objective to modulate the hemodialyzer removal capacities (convective and adsorptive capacities).

Materials(including heparin grafted specifications) as well as the sterilization process are identical to the Evodial hemodialyzer. Based on available preclinical data , a clinical study is requested to document in vivo the different prototypes removal capacities with respect to middle Molecular Weight (MW) reference toxins such as b2 Microglobulin and collect data with regards to protein loss.


Condition Intervention
End Stage Renal Disease (ESRD) Device: Evodial Device: Evodial+ Condition B1 Device: Evodial+ Condition B2 Device: Evodial+ Condition C

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +) - A Prospective, Monocenter, Open and Non-randomized Pilot Study

Further study details as provided by Baxter Healthcare Corporation:

Primary Outcome Measures:
  • Efficacy: Beta 2 Microglobulin elimination [ Time Frame: Change from T0 (dialysis start) at T4 hours (dialysis stop) ]

Secondary Outcome Measures:
  • Efficacy: -Elimination of Myoglobin,alpha 1 Microglobulin, alpha amylase and Factor D [ Time Frame: Change from T0 (dialysis start) at T 4hours (dialysis stop) ]
  • Efficacy:Profile of ultrafiltrated proteins [ Time Frame: at T4 hours ]
  • Safety: Follow-up of all AEs/SAEs [ Time Frame: during the study period ]
  • Safety: Measurement of Albumin loss [ Time Frame: At T4 hours ]
  • Efficacy: Cumulative Purified volume (Kt) [ Time Frame: At T4 hours ]
  • Safety: Total protein [ Time Frame: Change from T0 and T4 hours ]

Enrollment: 6
Study Start Date: October 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: Evodial
Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
Device: Evodial
Experimental: Evodial+ Condition B1
Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
Device: Evodial+ Condition B1
Experimental: Evodial+ Condition B2
Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
Device: Evodial+ Condition B2
Experimental: Evodial+ Condition C
Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
Device: Evodial+ Condition C

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Anuric patient (diuresis<300ml) ,
  2. ESRD patient treated for at least 3 months,
  3. Patient treated in HDF post-dilution,
  4. Vascular access functioning properly (Qb > 250 ml/min),
  5. Patient aged 18 years or more,
  6. Written consent to participate in the study (informed consent).

Exclusion Criteria:

  1. Patient with pre-dialytic albuminemia <3.3 g/dl(Nephelometry assay)
  2. Patient with known allergy to heparin or type II heparininduced thrombocytopenia (HIT type II);
  3. Patient under guardianship;
  4. Women pregnant or breast feeding;
  5. Patient included in other studies that could interfere with the goals of the current study.
  6. Patient that are not affiliated to the health system(beneficiary or dependent).
  7. Patient with positive serology (HIV, Hepatitis).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01783626

Locations
France
Hôpital Louis-Pasteur (Cherbourg-Octeville)
Cherbourg-Octeville, France, 50102
Sponsors and Collaborators
Baxter Healthcare Corporation
Gambro Lundia AB
Investigators
Study Director: Nathalie Loughraieb Gambro Industries
  More Information

Responsible Party: Baxter Healthcare Corporation
ClinicalTrials.gov Identifier: NCT01783626     History of Changes
Other Study ID Numbers: 1498
Study First Received: January 28, 2013
Last Updated: May 5, 2017

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on August 18, 2017